Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Youssef, Mohamed A F M ^a   Van der Veen, Fulco ^b   Al Inany, Hesham G ^a   Mochtar, Monique H ^c   Griesinger, Georg ^d   Nagi Mohesen, Mohamed ^e   Aboulfoutouh, Ismail ^f   van Wely, Madelon ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e BENI SUEF UNIVERSITY   (Egypt)

^f CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GESTAGEN; GONADORELIN AGONIST; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN; GONADORELIN;

DRUG EFFICACY; DRUG SAFETY; EMBRYO TRANSFER; HUMAN; IN VITRO FERTILIZATION; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; LUTEAL PHASE; MULTIPLE PREGNANCY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; SUBFERTILITY; SYSTEMATIC REVIEW; AGONISTS; DRUG EFFECTS; FEMALE; FERTILIZATION IN VITRO; GROWTH, DEVELOPMENT AND AGING; META ANALYSIS; OOCYTE; OOCYTE DONATION; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PROCEDURES;

CHORIONIC GONADOTROPIN; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTE DONATION; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84965190560     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008046.pub4     Document Type: Review

References (125)

1. Acevedo B, Jose Gomez-Palomares L, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertility and Sterility 2006;86(6):1682-7.
2. Babayof R, Margalioth J E, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al.Serum inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction 2006;21(5):1260-5.
3. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al.Non supplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. The Journal of Clinical Endocrinology and Metabolism 2003;88(9):4186-92. [DOI: 10.1210/jc.2002-021953].
4. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after co-treatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and Sterility 2008;89(1):84-91. [DOI: :10.1016/j.fertnstert.2007.02.002].
5. Fauser BC, De Jong D, Olivennes F, Warmsby H, Tay CJ, Itskovitz-Eldor J, Van Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism 2002;87(2):709-15.
6. Galindo A, Bodri D, Guillén JJ, Colodrón M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecology Endocrinolology 2009;25(1):60-6.
7. Humaidan P, Bredkjær HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction 2005;20(5):1213-20. [DOI: 10.1093/humrep/deh765].
8. Humaidan P, Bungum M, Andersen CY. Rescue of corpus luteum function with periovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online 2006;13(2):173-8.
9. Humaidan P, Bredkjær HE, Westergaard L, Andersen CY. 1500 IU hCG secures a normal clinical pregnancy outcome in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist. Fertility and Sterility 2010;93(3):847-54. [DOI: 10.1016/j.fertnstert.2008.12.042].
10. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al.GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reproduction 2013;28(9):2511-21.
11. Kolibianakis EM, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, et al.A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction 2005;20(10):2887-92. [DOI: 10.1093/humrep/dei150;: PUBMED].
12. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al.GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.. Reproductive BioMedicine Online 2009;19(4):486-92.
13. Ossina E, Yavorovskaya K, Kuzmichev L, Kornilov N, Belikov V, Belikova O, et al.Triggering of final oocyte maturation in GnRH antagonist IVFprotocols: triptorelin 0.1 mg versus hCG. A randomized multi centre trial. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27-30 June 2004;19(1):i99-i102.
14. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility 2011;95(3):1174-7.
15. Peña V, Chinea E, Sanabria V, Hernandez J, Palumbo A. Triggering final oocyte maturation with a GnRH agonist in egg donors does not reduce implantation and pregnancy rates and eliminates the risk of OHSS. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France, 1-4 July 2007;22(1):i123.
16. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Human Reproduction 2006;21(7):1894-900. [DOI: 10.1093/humrep/del072].
17. Segal S, Casper RF. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertility and Sterility 1992; Vol. 57, issue 6:1254-8.
18. Andersen CY, Humaidan P, Ejdrup HP, Bungum L, Grøndah ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Human Reproduction 2006;21(8):2126-30.
19. Murray AM, Soto-Albors C. Use of combined oral and vaginal estradiol and IM and vaginal progesterone in luteal phase of antagonist cycles triggered with GnRH agonist results in good clinical pregnancy rates. Fertility and Sterility 2011;45:S25.
20. Awwad JT, Hannoun AB, Khalil A, Younes ZM, Ghazeeri GS. Induction of final follicle maturation with a gonadotropin-releasing hormone agonist in women at risk of ovarian hyperstimulation syndrome undergoing gonadotropin stimulation and intrauterine insemination: proof-of-concept study. Clinical and Experimental Obstetrics and Gynecology 2012;39(4):436-9.
21. Bankowski B, Bracero N, King J, Garcia J, Wallach E, Vlahos N. Triggering ovulation with leuprolide acetate is associated with lower pregnancy rates. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27-30 June 2004;19 Suppl 1:i103.
22. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum R, Bustion S, et al.Comparison of the non supplemented luteal phase characteristics after recombinant luteinizing hormone (r) HCG, rLH or GnRH agonist for oocyte maturation in IVF. Abstracts of the 18th annual meeting of the ESHRE. 2002; Vol. 17, issue 7:55.
23. Bennett RA, Vidali A, Walker J, Navot D. Triggering ovulation with GnRH agonist to avoid ovarian hyperstimulation, frequently results in profound corpus luteum insufficiency. Fertility and Sterility 1997;68 Suppl 1:174-5.
24. Bodri D, Guillen JJ, Galind A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertility and Sterility 2009;91(2):365-71. [DOI: 10.1016/j.fertnstert.2007.11.049].
25. Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril. 2010;93(7):2418-20.
26. Bodri D. Low-dose hCG supplementation after GnRH agonist triggering: don't be too quick on the trigger.. Hum Reprod 2013;28(9):2315-7.
27. Bracero NJ, Jurema MW, Posada MN, Whelan JG, Garcia JE, Vlahos NP. Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotropin (hCG) after the use of ganirelix for in vitro fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertility and Sterility 2001;76 Suppl 3:93.
28. Bukulmez O, Rehman KS, Langley M, Carr BR, Doody KM, Doody KJ. Triggering ovulation by GnRH agonist leuprolide acetate does not adversely affect the number and quality of the oocytes as compared to recombinant hCG in oocyte donation cycles. Abstract of the annual meeting of ASRM 2005;84 Suppl(1):314-5.
29. Carone D, Vizziello GM, Schonauer LM, D'Amato G. Safety and efficacy of GnRH agonist to trigger ovulation in controlled ovarian hyperstimulation for ART with recombinant FSH and GnRH-antagonist in high responders (PCOD) patients. Abstracts of the 8th International Symposium on GnRH-analogues in Cancer and Human Reproduction.Salzburg, Austria 2005:A24.
30. Castillo JC, Dolz M, Evangelio B, Abad de Velasco L, Bonilla-Musoles F. Efficacy and security of luteal phase support with low doses of HCG in OHSS high risk patients triggered with GnRH agonists. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France, 1-4 July 2007;22(1):i 81.
31. Cerrillo M, Pacheco A, Rodríguez S, Mayoral M, Ruiz M, García Velasco JA. Differential regulation of VEGF, cadherin, and angiopoietin 2 by trigger oocyte maturation with GnRHa vs hCG in donors: try to explain the lower OHSS incidence. Abstracts of the 25th annual meeting of the ESHRE, Amsterdam, June 28-1 July, 2009;24(1):i60.
32. Check J, Nazari A, Barnea E, Weiss W, Vetter B. The efficacy of short-term gonadotrophin-releasing hormone agonists versus human chorionic gonadotrophin to enable oocyte release in gonadotrophin stimulated cycles. Human Reproduction 1993; Vol. 8:568-71.
33. Chen SL, Dong H, Xing FQ. Clinical study of buserelin, instead of hCG, used for triggering follicular maturation in infertile patients with PCOS. Fertility and Sterility 1998; Vol. 70, issue 3:S396.
34. Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, et al.Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Human Reproduction 2012;27(5):1351-6.
35. Cunha Filho J, Gratao A, Souza C, Freitas F, Vettori D, Passos E. Prospective randomized clinical trial to evaluate embryo quality (score) after GnRH agonist or HCG administration to induce oocyte maturation. Human Reproduction 2002; Vol. 17, issue 1:150, Abstract no: P-440.
36. Daneshmand ST, Shapiro BS, Garner FC, Aguirre M, Ross R. Cumulative pregnancy rates when using GnRH agonists instead of HCG for final oocyte maturation. Abstract of the annual meeting of ASRM 2006;86 Suppl(2):184-5.
37. De Jong D, Van Hooren EG, Macklon NS, Mannaerts BM, Fauser B. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics 2001;18:30-3.
38. Diaz I, Guillen A, Pacheco A, Requena A, Simon C, Garcia Velasco J. Final oocyte maturation with GnRH-agonist versus hCG in intrauterine insemination. Abstracts of the 19th annual meeting of the ESHRE.Madrid, Spain, June 29-July 2 2003;18(1):134.
39. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertility and Sterility 2010;94(3):1111-4.
40. Egbase PE, Grudzinskas JG, Al Sharhan M, Ashkenani L. HCG or GnRH agonist to trigger ovulation in GnRH antagonist-treated intrauterine insemination cycles: a prospective randomized study. Abstracts of the 18th Annual Meeting of the ESHRE, Vienna, Austria 2002 2002;17(1):2.
41. Eldar-Geva T, Zylber-Haran E, Babayof R, Halevy-Shalem T, Ben-Chetrit A, Tsafrir A, et al.Similar outcome for cryopreserved embryo transfer following GnRH antagonist/GnRH agonist, GnRH -antagonist/HCG or long protocol ovarian stimulation. Reproductive BioMedicine Online 2007;14(2):148-54.
42. Emperaire JC, Ruffie A, Audebert AJ. [Ovulation induction by endogenous LH released by the administration of an LHRH agonist after follicular stimulation for in vitro fertilization]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 1992; Vol. 21:489-94.
43. Engmann LA, Diluigi D, Schmidt J, Nulsen D, Maier C, Benadiva. Prevention of ovarian hyperstimulation syndrome (OHSS) with the use of gonadotropin releasing hormone (GnRH) agonist to trigger final oocyte maturation after cotreatment with GnRH antagonist in patients with polycystic ovarian syndrome (PCOS) or previous high response undergoing IVF treatment. A prospective randomized clinical trial. Abstract of the annual meeting of ASRM 2005;84 Suppl(1):96.
44. Engmann L, Siano L, Weitzman V, Nulsen J, Maier D, Benadiva C. Induction of oocyte maturation with GnRH agonists in high-risk patients undergoing IVF treatment does not adversely affect implantation rate. Fertility and Sterility 2006;86(1):797-8.
45. Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reproductive BioMedicine Online 2006; Vol. 13, issue 5:639-44.
46. Engmann L, Romak J, Nulsen J, Benadiva C, Peluso C. In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation. Fertility and Sterility 2011;96(1):198-202.
47. Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertility and Sterility 2012;97(3):531-3.
48. Erb TM, Vitek W, Wakim AN. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertility and Sterility 2010; Vol. 93, issue 2:374-8.
49. Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, et al.Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility 2013;100(3):742-7.
50. Galera F, Rayward J, Verdu V, Villafanez V, Manzanares MA, Garijo E. GnRH agonist triggered LH surge: P4, E2 levels. IVF outcome. Abstracts of the 21st Annual meeting of the ESHRE, Copenhagen, Denmark, 19-22, 2005;20(1):i 109.
51. Garcia-Velasco JA, Motta L, López A, Mayoral M, Cerrillo M, Pacheco A. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach. Fertility and Sterility 2010;94(7):2820-3.
52. Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertility and Sterility 2012;97(3):527-8.
53. Goto T, Oka C, Tatsuhiro T, Mukaida T, Takahashi K. Single dose nasal spray of gonadotropin releasing hormone (GnRH) agonist effectively matures oocytes for in vitro fertilization in an ovarian stimulation protocol using clomiphene citrate, gonadotropin, and GnRH antagonist. Abstracts of the Annual Meeting of the ASRM 2003;80 Suppl(3):6.
54. Griesinger G, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, et al.GnRH-agonist instead of hCG for final oocyte maturation in GnRH-antagonist cycles. 21st Annual Meeting of the European Society of Human Reproduction and Embryology, Copenhagen, Denmark, 19-22 June 2005 2005:i91.
55. Griesinger G, Kolibianakis EM, Papanikolaou EG, Diedrich K, Van Steirteghem A, Devroey PC. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertility and Sterility 2007;88(3):616-21. [DOI: 10.1016/j.fertnstert.2006.12.006].
56. Griesinger G, Von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al.Elective cryopreservation of all pro nuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Human Reproduction 2007;22(5):1348-52. [DOI: 10.1093/humrep/dem006].
57. Griesinger G, Berndt H, Schultz L, Depenbusch M, Schultze-Mosgau A. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. European Journal of Obstetric and Gynecologic Reproduction Biology 2010;149(2):190-4.
58. Griesinger G1, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertility and Sterility 2011;95(6):2029-33.
59. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility 2012;97(6):1316-20.
60. Herrero L, Pareja S, Losada C, et al.Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome. Fertility and Sterility 2010;95(3):1137-40.
61. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding Andersen C. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertility and Sterility 2011; Vol. 95, issue 6:2034-8.
62. Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, et al.Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles. Human Reproduction 2012; Vol. 27, issue 11:3259-72.
63. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Human Reproduction 2012;27(3):753-9.
64. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 2000;15(9):1965-8.
65. Johnston-MacAnanny EB, DiLuigi AJ, Benadiva CA, Maier DB, Nulsen JC, Engmann LL. Choice of medication for oocyte maturation for in vitro fertilization (IVF) gonadotropin releasing hormone (GnRH) antagonist cycles; Human chorionic gonadotropin (HCG) vs leuprolide acetate (LA). Abstract of the annual meeting of ASRM 2007;88 Suppl(1):142.
66. Joo JK, Choi JR, Son JB, Ko GR, Lee KS. Preliminary clinical outcome of novel strategy for the maximization of cumulative pregnancy rates per retrieval in normal responders. Clinical and Experimental Reproductive Medicine 2012;39(1):33-9.
67. Kaur H, Krishna D, Shetty N, Krishnan S, Srinivas MS, Rao KA. Effect of pre-ovulatory single dose GnRH agonist therapy on IVF outcome in GnRH antagonist; a prospective study. Journal of Reproduction and Infertility 2012;13(4):225-31.
68. Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin-releasing hormone antagonist protocol the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. Acta Obstetricia et Gynecologica Scandinavica 2012;91(6):643-7.
69. Krause BT, Ohlinger O. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2006;126:87-92.
70. Kummer NE, Feinn RS, Griffin DW, Nulsen JC, Benadiva CA, Engmann LL. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. Human Reproduction 2013;28(1):152-9.
71. LaMonica R, Siano LJ, Nulsen JC, Maier DB, Benadiva CA, Engmann LL. Elective cryopreservation of all embryos after GnRH agonist trigger is not justified because of the comparable success rates between fresh and cryo-thawed embryo transfers. Abstracts of the annual meeting of ASRM 2007;88 Suppl(1):135.
72. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, et al.Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertility and Sterility 1994;62(1):35-41.
73. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, et al.Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles [erratum appears in Fertil Steril 1995 Mar 63(3):684-5]. Fertility and Sterility 1994; Vol. 62, issue 1:35-41.
74. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome. Human Reproduction 1996;11(7):1399-402.
75. Lin YH, Huang MZ, Hwang JL, Chen HJ, Hsieh BC, Huang LW, et al.Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels a retrospective study. Journal of Assisted Reproduction and Genetics 2013;30(6):753-9.
76. Lin MH, Shao-Ying Wu F, Kuo-Kuang lee R, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertilty and Sterility 2013;100(5):1296-302.
77. Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al.Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Human Reproduction 2013;28(9):2529-36.
78. Loumaye E, Pirard C, Donnez J. GnRH agonist as a novel luteal support: results of a pilot study. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27 - 30 June 2004;19(1):i4.
79. Loumaye E, Pirard C, Donnez J. Efficacy of GnRH agonist as luteal support: results of a prospective, randomized, comparative study. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France 1-4 July 2007;22(1):i82.
80. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al.GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study [Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. A randomized, prospective, controlled, assessor-blind study, comparing triptorelin vs rhCG as trigger oocyte maturation in oocyte donors]. 2007 Fertility and Sterility; Vol. 88, issue 1:34.
81. Meltzer S, Girsh E, Shults A, Katz N, Zohav E, Tur-Kaspa I. Prevention of ovarian hyperstimulation syndrome in high responders undergoing IVF treatment with GnRH antagonist combined with single dose of GnRH agonist, instead of HCG, for the induction of oocyte maturation. Abstracts of the 18th Annual Meeting of the ESHRE 2002;17 Suppl1:89.
82. Nelson SM. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thrombosis Research 2013;Suppl 1:S1-S3.
83. Nevo O, Eldar-Geva T, Kol BS, Itskovitz-Eldor J. Lower levels of inhibin A and pro-C during the luteal phase after triggering oocyte maturation with a gonadotropin releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 2003;79(5):1123-8. [DOI: doi:10.1016/S0015-0282(03)00177-8].
84. Olivennes F. Induction of final oocyte maturation by a single dose of GNRH agonist after ganirelix treatment. Gynecological Endocrinology 2001;15(Suppl 2):7.
85. Orvieto R, Zagatsky I, Yullzari-Roll V, La Marca A, Fisch B. Substituting human gonadotropin by gonadotropin-releasing hormone to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecological Endocrinology 2006;22(8):437-40.
86. Orvieto R, Nahum R, Zohav E, Liberty G, Anteby EY, Meltcer S. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecological Endocrinology 2013;29(1):51-3.
87. Parneix I, Emperaire JC, Ruffie A, Parneix P. Triggering of ovulation using different regimens of gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Gynecologie, Obstetrique & Fertilite 2001; Vol. 29, issue 2:100-5.
88. Peñarrubia J, Balasch J, Fábregues F, Creus M, Casamitjana R, Ballescá JL, et al.Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulations in gonadotrophin-stimulated cycles. Human Reproduction 1998;13(12):3315-8.
89. Ricciarelli E, Acevedo-Martin B, Gomez-Palomares JL, Pareja A, Hernandes ER. Triggering ovulation with GnRH agonists does not compromise embryo implantability. Human Reproduction 2006; Vol. 21, issue Suppl:i35.
90. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, et al.Can pregnancy rate be improved in gonadotropin -releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertility and Sterility 2008;90(4):1087-93. [DOI: 10.1016/j.fertnstert.2007.07.1316].
91. Schmidt Sarosi C, Kaplan DR, Sarosi P, Essig MN, Licciardi FL, Keltz M, et al.Ovulation triggering in clomiphene citrate stimulating cycles: human chronic gonadotropin versus a gonadotropin releasing hormone agonist. Journal of Assisted Reproduction & Genetics 1995; Vol. 12, issue 3:167-73.
92. Schmidt-Sarosi C, Kaplan DR, Sarosi P, Essig MN, Licciardi FL, Keltz M, et al.Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist. Journal of Assisted Reproduction and Genetics 1995;12(3):167-74.
93. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction 2013;28(9):2522-8.
94. Shalev E, Geslevich Y, Matilsky M, Ben Ami M. Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment. Human Reproduction 1995; Vol. 10:2541-4.
95. Shanis BS, Check JH. Efficacy of gonadotropin-releasing hormone agonists to induce ovulation following low-dose human menopausal gonadotropin stimulation. Recent Progress in Hormone Research 1995:483-6.
96. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertility and Sterility 2007;88(1):237. [DOI: 10.1016/j.fertnstert.2006.11.069].
97. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertility and Sterility 2008;90(1):231-3.
98. Shapiro BS, Daneshmand ST, Garner FC, et al.Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertility and Sterility 2011;95(8):2715-7.
99. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropn-releasing hormone agonist. Fertility and Sterility 2011;95(2):826-8.
100. Sismanoglu A1, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. Journal of Assisted Reproduction and Genetics 2009;26(5):251-6.
101. Toner JP, Denis AL, Hasty LA, Carpenter S, Bates W. Lupron trigger experience in GnRH antagonist ART cycles. Abstracts of the Annual meeting of the ASRM 2006;86(3):S118-9.
102. Westergaard L, Andersen CY, Humaidan P, Bredkjær HE, Bungum L, Bungum M, et al.Significant reduction of clinical pregnancy and implantation rates by use of GnRH agonist (Buserelin) as compared to hCG to induce ovulation in FSH/GnRH antagonist treated IVF/ICSI cycles. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Lyon, 27-30 June 2004;19(1):i3.
103. Wilkinson SC, Walker SA, Hayes BA, Donesky BW, Bird JS, Anderson AR. Gonadotropin releasing hormone (GnRH) agonist trigger following antagonist protocols in anonymous oocyte donors minimizes ovarian hyperstimulation syndrome. Abstract of the annual meeting of ASRM 2007;88(1):S131.
104. Yding Andersen C, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl F. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction. Human Reproduction 1993; Vol. 8, issue 6:840-3.
105. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome. Human Reproduction Update 2003;9:77-96.
106. Emperaire JC, Parneix I, Ruffie A. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reproductive Biomedicine Online 2004;9:22-7.
107. Felberbaum PE, Reissmannb T, Kiipkera W, Bauera O, Al Hasania S, Diedrich C, et al.Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (cetrorelix) in women with tubal infertility. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1995;61:151-5.
108. Forman R, Fries N, Tastart J, Belaisch J, Hazout A, Frydman R. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertility and Sterility 1998;49:118-22.
109. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstetrical & Gynecological Survey 1989;44(6):430-40.
110. Gonen Y, Balakier H, Powell W, Casper RF. Use of GnRH agonist to trigger follicular maturation for in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism 1990;71:918-23.
111. Griesinger G, Diedrich K, Dovroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Human Reproduction Update 2006;12(2):159-68. [DOI: 10, 1093/humrupd/dmi045].
112. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochrane-handbook.org.
113. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Human Reproduction 2009;24(10):2389-94.
114. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonists the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 2004;81(1):1-5.
115. Kol S. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. Journal of Assisted Reproduction and Genetics 2008;25:63-6. [DOI: 10.1007/s10815-008-9198-1].
116. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reproductive Biomedicine Online 2013;26(3):226-30.
117. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;2012 Dec 12;12:MR000033:doi: 10.1002/14651858.MR000033.pub2. Review..
118. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 1992;58:249-61.
119. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with GnRH antagonist. Fertility and Sterility 1996;66:151-3.
120. Simon C, Cano F, Valbuena D, Remohi J, Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum estradiol concentrations in high and normal responders. Human Reproduction 1995;10:2432-7.
121. Simon C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Rehmohi J, et al.Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertility and Sterility 1998;70:234-9.
122. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. Journal of Reproductive Immunology 2002;55:123-30.
123. Tay CC. Use of gonadotropin-releasing hormone agonist to trigger ovulation. Human Fertility 2002;5:G35-7.
124. Valbuena D, Martin J, de Palbo JL, Remohi J, Pellicer A, Simon C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertility and Sterility 2001;76:962-8.
125. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010;11(CD008046):doi: 10.1002/14651858.CD008046.pub2..